Gene-environment and gene-treatment interactions in type 2 diabetes: Progress, pitfalls, and prospects

Diabetes Care

Volumn 36, Issue 5, 2013, Pages 1413-1421

  Franks, Paul W ^a,b,c   Pearson, Ewan ^d   Florez, Jose C ^e,f,g  

^a LUND UNIVERSITY   (Sweden)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ATM GENE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; GENE; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GLYCEMIC LOAD; HNF1A GENE; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHARMACOGENETICS; PHYSICAL ACTIVITY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

DIABETES MELLITUS, TYPE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE;

EID: 84876802154     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2211     Document Type: Review

References (67)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053 (Pubitemid 38579764)
2. Ayach BB, Korda H. Type 2 diabetes epidemic in First Nations people of Canada. Ethn Dis 2010;20:300-303
3. King H, Rewers M; WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993;16:157-177 (Pubitemid 23013841)
4. Franks PW, Looker HC, Kobes S, et al. Gestational glucose tolerance and risk of type 2 diabetes in young Pima Indian offspring. Diabetes 2006;55:460-465 (Pubitemid 43343276)
5. Schulz LO, Bennett PH, Ravussin E, et al. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care 2006;29:15866-1871
6. Neel JV. Diabetes mellitus: A "thrifty" genotype rendered detrimental by "progress" ? Am J Hum Genet 1962;14:353-362
7. Bouchard C. Genes and obesity. Preface. Prog Mol Biol Transl Sci 2010;94:xiii
8. Southam L, Soranzo N, Montgomery SB, et al. Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes-and obesity-susceptibility variants? Diabetologia 2009; 52:1846-1851
9. Aschard H, Chen J, Cornelis MC, Chibnik LB, Karlson EW, Kraft P. Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases. Am J Hum Genet 2012;90:962-972
10. Franks PW, Mesa JL, Harding AH, Wareham NJ. Gene-lifestyle interaction on risk of type 2 diabetes. Nutr Metab Cardiovasc Dis 2007;17:104-124 (Pubitemid 46240794)
11. Luan J, Browne PO, Harding AH, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001;50: 686-689 (Pubitemid 32195237)
12. Kahara T, Takamura T, Hayakawa T, et al. PPARgamma gene polymorphism is associated with exercise-mediated changes of insulin resistance in healthy men. Metabolism 2003;52:209-212 (Pubitemid 36388845)
13. Franks PW, Luan J, Browne PO, et al. Does peroxisome proliferator- activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism 2004;53:11-16 (Pubitemid 38071929)
14. Memisoglu A, Hu FB, Hankinson SE, et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003;12:2923-2929 (Pubitemid 37442020)
15. Robitaille J, Després JP, Pérusse L, Vohl MC. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec Family Study. Clin Genet 2003; 63:109-116 (Pubitemid 36949904)
16. Lindi VI, Uusitupa MI, Lindström J, et al.; Finnish Diabetes Prevention Study. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002;51:2581-2586 (Pubitemid 34827410)
17. Palla L, Higgins JP, Wareham NJ, Sharp SJ. Challenges in the use of literature-based meta-analysis to examine geneenvironment interactions. Am J Epidemiol 2010;171:1225-1232
18. Franks PW, Nettleton JA. Invited commentary: Gene X lifestyle interactions and complex disease traitsdinferring cause and effect from observational data, sine qua non. Am J Epidemiol 2010;172:992-997; discussion 998-999
19. Wong MY, Day NE, Luan JA, Chan KP, Wareham NJ. The detection of geneenvironment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement? Int J Epidemiol 2003;32:51-57 (Pubitemid 36503473)
20. Morris AP, Voight BF, Teslovich TM, et al.; DIAGRAM Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysi-ology of type 2 diabetes. Nat Genet 2012; 44:981-990
21. Scott RA, Lagou V, Welch RP, et al.; DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012;44:991-1005
22. Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 2008;57:95-101
23. Rampersaud E, Mitchell BD, Pollin TI, et al. Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med 2008;168:1791-1797
24. Franks PW, Jablonski KA, Delahanty LM, et al.; Diabetes Prevention Program Research Group. Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia 2008; 51:2214-2223
25. Kilpeläinen TO, Qi L, Brage S, et al. Physical activity attenuates the influence of FTO variants on obesity risk: A meta-analysis of 218, 166 adults and 19, 268 children. PLoS Med 2011;8:e1001116
26. Yang J, Loos RJ, Powell JE, et al. FTO genotype is associated with phenotypic variability of body mass index. Nature 2012;490:267-272
27. Brito EC, Lyssenko V, Renström F, et al. Previously associated type 2 diabetes variants may interact with physical activity to modify the risk of impaired glucose regulation and type 2 diabetes: A study of 16, 003 Swedish adults. Diabetes 2009;58: 1411-1418
28. Sonestedt E, Lyssenko V, Ericson U, et al. Genetic variation in the glucose-dependent insulinotropic polypeptide receptor modifies the association between carbohydrate and fat intake and risk of type 2 Diabetes in the Malmö Diet and Cancer Cohort.JJClin Endocrinol Metab 2012;97:E810-E818
29. Hindy G, Sonestedt E, Ericson U, et al. Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes. Diabetologia 2012;55:2646-2654
30. Cornelis MC, Qi L, Kraft P, Hu FB. TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. Am J Clin Nutr 2009;89:1256-1262
31. Nettleton JA, McKeown NM, Kanoni S, et al.; MAGIC Investigators. Interactions of dietary whole-grain intake with fasting glucose-and insulin-related genetic loci in individuals of European descent: A meta-analysis of 14 cohort studies. Diabetes Care 2010;33:2684-2691
32. Qi L, Cornelis MC, Zhang C, van Dam RM, Hu FB. Genetic predisposition, Western dietary pattern, and the risk of type 2 diabetes in men. Am J Clin Nutr 2009;89:1453-1458
33. Nettleton JA, Hivert MF, Lemaitre RN, et al. Meta-analysis investigating associations between healthy diet and fasting glucose and insulin levels and modification by loci associated with glucose ho-meostasis in data from 15 cohorts. Am J Epidemiol 2013;177:103-115
34. Perry JR, Voight BF, Yengo L, et al.; MAGIC; DIAGRAM Consortium; GIANT Consortium. Stratifying type 2 diabetes cases by BMI identifies genetic risk variants in LAMA1 and enrichment for risk variants in lean compared to obese cases. PLoS Genet 2012;8:e1002741
35. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403 (Pubitemid 34437694)
36. Tuomilehto J, Lindström J, Eriksson JG, et al.; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350 (Pubitemid 32378388)
37. Moore AF, Jablonski KA, McAteer JB, et al.; Diabetes Prevention Program Research Group. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 2008;57:2503-2510
38. Jablonski KA, McAteer JB, de Bakker PI, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010;59:2672-2681
39. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355:241-250 (Pubitemid 44079339)
40. Moore AF, Jablonski KA, Mason CC, et al.; Diabetes Prevention Program Research Group. The association of ENPP1 K121Q with diabetes incidence is abolished by lifestyle modification in the diabetes prevention program. J Clin Endocrinol Metab 2009;94:449-455
41. Hivert MF, Jablonski KA, Perreault L, et al.; DIAGRAM Consortium; Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes 2011;60:1340-1348
42. Do R, Xie C, Zhang X, et al.; INTER-HEART investigators. The effect of chromosome 9p21 variants on cardiovascular disease may be modified by dietary intake: evidence from a case/control and a prospective study. PLoS Med 2011;8:e1001106
43. Qi Q, Chu AY, Kang JH, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med 2012;367:1387-1396
44. Franks PW. Gene 3 environment interactions in type 2 diabetes. Curr Diab Rep 2011;11:552-561
45. Kraft P, Yen YC, Stram DO, Morrison J, Gauderman WJ. Exploiting geneenvironment interaction to detect genetic associations. Hum Hered 2007;63:111-119
46. Manning AK, LaValley M, Liu CT, et al. Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP 3 environment regression coefficients. Genet Epidemiol 2011;35:11-18
47. Manning AK, Hivert MF, Scott RA, et al.; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; Multiple Tissue Human Expression Resource (MUTHER) Consortium. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 2012;44:659-669
48. Paré G, Cook NR, Ridker PM, Chasman DI. On the use of variance per genotype as a tool to identify quantitative trait interaction effects: A report from the Women's Genome Health Study. PLoS Genet 2010;6:e1000981
49. Visscher PM, Posthuma D. Statistical power to detect genetic Loci affecting environmental sensitivity. Behav Genet 2010;40: 728-733
50. Pearson ER. Pharmacogenetics in diabetes. Curr Diab Rep 2009;9:172-181
51. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharma-coepigenomic perspective. Pharmacoge-nomics 2011;12:1161-1191
52. Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med 2011; 3:76
53. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003;362: 1275-1281 (Pubitemid 37324255)
54. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT. No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 2003;26:3191-3192 (Pubitemid 37339526)
55. Becker ML, Visser LE, van Schaik RHN, Hofman A, Uitterlinden AG, Stricker BHC. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes 2009;58: 745-749
56. Florez JC, Jablonski KA, Taylor A, et al.; Diabetes Prevention Program Research Group. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care 2012;35:1864-1867
57. Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharma-cogenetics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117-120
58. van Leeuwen N, Nijpels G, Becker ML, et al. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: A replication and meta-analysis of five cohorts. Diabetologia 2012;55:1971-1977
59. Greeley SA, Naylor RN, Philipson LH, Bell GI. Neonatal diabetes: An expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep 2011;11:519-532
60. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326
61. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17: 448-453
62. Voy BH. Systems genetics: A powerful approach for gene-environment interactions. J Nutr 2011;141:515-519
63. Hu FB. Metabolic profiling of diabetes: from black-box epidemiology to systems epidemiology.ClinChem 2011;57:1224-1226
64. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208-2219
65. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-2232
66. de Miguel-Yanes JM, Shrader P, Pencina MJ, et al.; MAGIC Investigators; DIAGRAM+ Investigators. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 2011;34: 121-125
67. Renström F, Payne F, Nordström A, et al.; GIANT Consortium. Replication and extension of genome-wide association study results for obesity in 4923 adults from northern Sweden. Hum Mol Genet 2009; 18:1489-1496